219 related articles for article (PubMed ID: 11148027)
21. Oncoprotein MDM2 conceals the activation domain of tumour suppressor p53.
Oliner JD; Pietenpol JA; Thiagalingam S; Gyuris J; Kinzler KW; Vogelstein B
Nature; 1993 Apr; 362(6423):857-60. PubMed ID: 8479525
[TBL] [Abstract][Full Text] [Related]
22. p53 mediated death of cells overexpressing MDM2 by an inhibitor of MDM2 interaction with p53.
Wasylyk C; Salvi R; Argentini M; Dureuil C; Delumeau I; Abecassis J; Debussche L; Wasylyk B
Oncogene; 1999 Mar; 18(11):1921-34. PubMed ID: 10208414
[TBL] [Abstract][Full Text] [Related]
23. MDM2 and MDM4: p53 regulators as targets in anticancer therapy.
Toledo F; Wahl GM
Int J Biochem Cell Biol; 2007; 39(7-8):1476-82. PubMed ID: 17499002
[TBL] [Abstract][Full Text] [Related]
24. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2.
Vassilev LT; Vu BT; Graves B; Carvajal D; Podlaski F; Filipovic Z; Kong N; Kammlott U; Lukacs C; Klein C; Fotouhi N; Liu EA
Science; 2004 Feb; 303(5659):844-8. PubMed ID: 14704432
[TBL] [Abstract][Full Text] [Related]
25. MDM2 interaction with nuclear corepressor KAP1 contributes to p53 inactivation.
Wang C; Ivanov A; Chen L; Fredericks WJ; Seto E; Rauscher FJ; Chen J
EMBO J; 2005 Sep; 24(18):3279-90. PubMed ID: 16107876
[TBL] [Abstract][Full Text] [Related]
26. Flexible lid to the p53-binding domain of human Mdm2: implications for p53 regulation.
McCoy MA; Gesell JJ; Senior MM; Wyss DF
Proc Natl Acad Sci U S A; 2003 Feb; 100(4):1645-8. PubMed ID: 12552135
[TBL] [Abstract][Full Text] [Related]
27. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
28. Mdm2 inhibition of p53 induces E2F1 transactivation via p21.
Wunderlich M; Berberich SJ
Oncogene; 2002 Jun; 21(28):4414-21. PubMed ID: 12080472
[TBL] [Abstract][Full Text] [Related]
29. A closer view of an oncoprotein-tumor suppressor interaction.
Shair MD
Chem Biol; 1997 Nov; 4(11):791-4. PubMed ID: 9384532
[TBL] [Abstract][Full Text] [Related]
30. QSAR: hydropathic analysis of inhibitors of the p53-mdm2 interaction.
Galatin PS; Abraham DJ
Proteins; 2001 Nov; 45(3):169-75. PubMed ID: 11599019
[TBL] [Abstract][Full Text] [Related]
31. Turning the key on p53.
Lane DP; Fischer PM
Nature; 2004 Feb; 427(6977):789-90. PubMed ID: 14985740
[No Abstract] [Full Text] [Related]
32. Design, synthesis, and evaluation of novel boronic-chalcone derivatives as antitumor agents.
Kumar SK; Hager E; Pettit C; Gurulingappa H; Davidson NE; Khan SR
J Med Chem; 2003 Jul; 46(14):2813-5. PubMed ID: 12825923
[TBL] [Abstract][Full Text] [Related]
33. The MDM2-p53 interaction.
Moll UM; Petrenko O
Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
[TBL] [Abstract][Full Text] [Related]
34. A genetic approach to mapping the p53 binding site in the MDM2 protein.
Freedman DA; Epstein CB; Roth JC; Levine AJ
Mol Med; 1997 Apr; 3(4):248-59. PubMed ID: 9131587
[TBL] [Abstract][Full Text] [Related]
35. Small-molecule inhibitors of the p53-MDM2 interaction.
Vu BT; Vassilev L
Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
[TBL] [Abstract][Full Text] [Related]
36. Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
Popowicz GM; Czarna A; Holak TA
Cell Cycle; 2008 Aug; 7(15):2441-3. PubMed ID: 18677113
[TBL] [Abstract][Full Text] [Related]
37. A nonpeptidic sulfonamide inhibits the p53-mdm2 interaction and activates p53-dependent transcription in mdm2-overexpressing cells.
Galatin PS; Abraham DJ
J Med Chem; 2004 Aug; 47(17):4163-5. PubMed ID: 15293988
[TBL] [Abstract][Full Text] [Related]
38. Targeting the p53-MDM2 interaction to treat cancer.
Klein C; Vassilev LT
Br J Cancer; 2004 Oct; 91(8):1415-9. PubMed ID: 15452548
[TBL] [Abstract][Full Text] [Related]
39. Mdm2 promotes the rapid degradation of p53.
Haupt Y; Maya R; Kazaz A; Oren M
Nature; 1997 May; 387(6630):296-9. PubMed ID: 9153395
[TBL] [Abstract][Full Text] [Related]
40. Development of cell-penetrating peptide-based drug leads to inhibit MDMX:p53 and MDM2:p53 interactions.
Philippe G; Huang YH; Cheneval O; Lawrence N; Zhang Z; Fairlie DP; Craik DJ; de Araujo AD; Henriques ST
Biopolymers; 2016 Nov; 106(6):853-863. PubMed ID: 27287767
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
